Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
A new study shows that GLP-1 drugs offer health benefits such as reducing risks for heart disease but also carry potential ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Commonly used diabetes drugs could lower the risk of cardiometabolic conditions but heighten the risk of gastrointestinal and ...
Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...
The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes ...
Despite constraints exerted by GLP-1RAs on bariatric surgery volumes, shares in Intuitive Surgical surged following a ...